Article info
PDFResearch Article
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
- ↵a +46 46 540 82 49 amk{at}alligatorbioscience.com
- ↵b niina{at}veitonmaki.com
- ↵c khd{at}alligatorbioscience.com
- ↵d adn{at}alligatorbioscience.com
- ↵e kae{at}alligatorbioscience.com
- ↵f saf{at}alligatorbioscience.com
- ↵g lvs{at}alligatorbioscience.com
- ↵h mit{at}alligatorbioscience.com
- ↵i dwu{at}alligatorbioscience.com
- ↵j dwu{at}alligatorbioscience.com
- ↵k maj{at}alligatorbioscience.com
- ↵l anr{at}alligatorbioscience.com
- ↵m ida{at}alligatorbioscience.com
- ↵n maw{at}alligatorbioscience.com
- ↵o evn{at}alligatorbioscience.com
- ↵p kab{at}alligatorbioscience.com
- ↵q chf{at}alligatorbioscience.com
- ↵r pen{at}alligatorbioscience.com
- ↵s pek{at}alligatorbioscience.com
Citation
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Publication history
- Received December 27, 2018
- Accepted March 19, 2019
- First published April 11, 2019.
Online issue publication
January 08, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.